Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
In a recent transaction filed with the Securities and Exchange Commission, Pax Margaret, a director at Repligen Corp (NASDAQ:RGEN), purchased 250 shares of the company’s common stock. The shares were acquired at a price of $150.69 each, amounting to a total transaction value of $37,672. Following this acquisition, Margaret now holds 1,043 shares of Repligen directly. The company, currently valued at $8.1 billion, has seen its stock trade between $113.50 and $200.23 over the past 52 weeks. According to InvestingPro data, analysts have set price targets ranging from $155 to $225, suggesting potential upside.
Repligen, a company based in Waltham, Massachusetts, is known for its work in the life sciences sector, specifically in the production of biological products. With annual revenue of $634 million and a strong liquidity position, the company maintains a healthy current ratio of 8.41. While currently not profitable, InvestingPro analysis indicates expected profitability this year, with 12 additional key insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Repligen Corporation has reported its fourth-quarter and full-year financial results for 2024, with fourth-quarter revenue reaching $167.5 million, a slight increase from the previous year. The full-year revenue amounted to $634.4 million, aligning with H.C. Wainwright’s projections. Looking forward, Repligen’s 2025 revenue guidance is set between $685 million and $710 million, with analysts at H.C. Wainwright forecasting $697.1 million. In a strategic move, Repligen has acquired a bioprocessing desktop portfolio for $70 million, expected to add $10 million in sales for the current year, although it will slightly dilute earnings before interest and taxes. Leerink Partners maintains an Outperform rating with a $200 target, while Canaccord Genuity has increased its price target to $170, maintaining a Hold rating. Evercore ISI has begun coverage on Repligen with an In Line rating and a $155 price target, noting the company’s potential for growth as the market recovers. Repligen’s recent acquisition enhances its upstream capabilities and complements its existing technology portfolio, with MAVEN/MAVERICK and REBEL playing significant roles in its long-term strategy. Despite recent challenges, Repligen’s management anticipates revenue growth of 10%-14% for 2025, excluding COVID-19 impacts, with adjusted earnings per share projected between $1.67 and $1.76.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.